Clinical Trial Update: Eculizumab in Primary MPGN [Phase 2]

View source ↗

Summary

Phase 2 trial update for eculizumab in membranoproliferative glomerulonephritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranoproliferative Glomerulonephritis

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Membranoproliferative Glomerulonephritis | Phase 2 | Status: COMPLETED